Patents by Inventor Marcus Jerling

Marcus Jerling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating diabetes
    Patent number: 8822473
    Abstract: Methods are provided for lowering plasma level of HbA1c in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease and slowing or delaying the development of or worsening of hyperglycemia in a diabetic, pre-diabetic, or non-diabetic patient.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: September 2, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Andrew Wolff, Marcus Jerling
  • USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
    Publication number: 20090111826
    Abstract: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.
    Type: Application
    Filed: February 13, 2008
    Publication date: April 30, 2009
    Inventors: Louis Lange, Marcus Jerling, Andrew Wolff
  • USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE
    Publication number: 20080299195
    Abstract: This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose.
    Type: Application
    Filed: March 24, 2008
    Publication date: December 4, 2008
    Inventors: Brent Blackburn, Marcus Jerling, Andrew Wolff
  • USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE
    Publication number: 20080233191
    Abstract: This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose.
    Type: Application
    Filed: March 20, 2008
    Publication date: September 25, 2008
    Inventors: Brent Blackburn, Marcus Jerling, Andrew Wolff
  • METHOD OF TREATING DIABETES
    Publication number: 20080009503
    Abstract: Methods are provided for lowering plasma level of HbA1c in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease and slowing or delaying the development of or worsening of hyperglycemia in a diabetic, pre-diabetic, or non-diabetic patient.
    Type: Application
    Filed: May 31, 2007
    Publication date: January 10, 2008
    Inventors: Andrew Wolff, Marcus Jerling